ストックスクリーナーアプリを入手
18.92
1.34%
0.25
アフターアワーズ：
18.96
0.04
+0.21%
前日終値:
$18.67
開ける：
$18.99
24時間の取引高:
2.51M
Relative Volume:
1.46
時価総額：
$3.00B
収益：
$1.27M
当期純損益:
$-512.54M
株価収益率:
-6.3723
EPS:
-2.9691
ネットキャッシュフロー:
$-422.10M
1週間 パフォーマンス:
-5.68%
1か月 パフォーマンス:
-8.38%
6か月 パフォーマンス:
+27.07%
1年 パフォーマンス:
+18.32%
1日の値動き範囲:
$18.33
$19.40
1週間の範囲:
$18.10
$20.17
52週間の値動き範囲:
$12.58
$23.77
Denali Therapeutics Inc Stock (DNLI) Company Profile
名前
Denali Therapeutics Inc
セクター
電話
(650) 866-8547
住所
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
18.92 | 2.96B | 1.27M | -512.54M | -422.10M | -2.9691 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2026-02-24 | 開始されました | Wolfe Research | Peer Perform |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-04-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | 再開されました | Morgan Stanley | Overweight |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2025-01-07 | 開始されました | Robert W. Baird | Outperform |
| 2025-01-03 | 開始されました | William Blair | Outperform |
| 2024-12-16 | アップグレード | Stifel | Hold → Buy |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-10-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | 開始されました | Citigroup | Buy |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-09-06 | 開始されました | B. Riley Securities | Buy |
| 2023-01-30 | 開始されました | SVB Securities | Outperform |
| 2022-12-05 | 開始されました | Cowen | Outperform |
| 2022-11-02 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-11-02 | 開始されました | BofA Securities | Buy |
| 2022-06-23 | 開始されました | Berenberg | Buy |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-09-21 | 開始されました | Oppenheimer | Outperform |
| 2021-09-01 | 開始されました | SMBC Nikko | Outperform |
| 2021-05-18 | 開始されました | UBS | Buy |
| 2021-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-16 | ダウングレード | BTIG Research | Buy → Neutral |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-08-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-13 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-02-28 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-02-24 | 開始されました | Jefferies | Buy |
| 2020-02-19 | 開始されました | Stifel | Hold |
| 2020-01-27 | アップグレード | Goldman | Neutral → Buy |
| 2019-09-26 | 開始されました | Wedbush | Neutral |
| 2019-09-13 | 開始されました | Nomura | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-06-26 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-11-12 | 開始されました | Janney | Buy |
| 2018-03-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2018-01-02 | 開始されました | Evercore ISI | Outperform |
| 2018-01-02 | 開始されました | Goldman | Neutral |
| 2018-01-02 | 開始されました | JP Morgan | Overweight |
| 2018-01-02 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Denali Therapeutics Inc (DNLI) 最新ニュース
Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval - The Motley Fool
MSN Money - MSN
Assessing Denali Therapeutics (DNLI) Valuation After Takeda Ends DNL593 Partnership - Sahm
Why Denali Therapeutics (DNLI) Is Down 8.2% After Takeda Exits DNL593 Collaboration And Returns Rights - Yahoo Finance
DNLI gains 25.4% year to date: Should you buy, sell or hold the stock? - MSN
D.A. Davidson & CO. Invests $1.77 Million in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform - Seeking Alpha
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Japanese Stocks Amid Restructuring Drive? - Yahoo Finance
Precision Trading with Denali Therapeutics Inc. (DNLI) Risk Zones - Stock Traders Daily
Denali Therapeutics Inc. $DNLI Shares Bought by Pictet Asset Management Holding SA - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Trading Down 8.1%What's Next? - MarketBeat
Denali Therapeutics Reclaims DNL593 Rights After Takeda Collaboration Ends - HarianBasis.co
What Makes Denali Therapeutics (DNLI) One of the Best Biotech Stocks to Invest in - Yahoo Finance
10 Best Biotech Stocks with Highest Upside Potential - Insider Monkey
Denali gains on FDA approval of lead asset - MSN
DNLI Stock Price, Quote & Chart | DENALI THERAPEUTICS INC (NASDAQ:DNLI) - ChartMill
FDA clears Denali Therapeutics drug as first brain-penetrating biologic for rare disease - MSN
Denali Therapeutics dips after pricing $200M equity offering - MSN
B. Metzler seel. Sohn & Co. AG Makes New $1.84 Million Investment in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Stock Rating Lowered by Wall Street Zen - MarketBeat
Bernstein Upgrades Takeda Pharmaceutical (TAK) to Outperform - Yahoo Finance Singapore
Leerink Partners Cuts Denali Therapeutics (NASDAQ:DNLI) Price Target to $35.00 - MarketBeat
Denali CEO’s ‘greatest professional moment’ arrives as rare disease drug launches - BioSpace
Denali Therapeutics (DNLI) CMO restates 204,402-share insider stake in Form 3/A - Stock Titan
Form DEFA14A Denali Therapeutics Inc. - StreetInsider
[ARS] Denali Therapeutics Inc. SEC Filing - Stock Titan
Denali Therapeutics (NASDAQ: DNLI) sets 2026 virtual meeting and pay vote - Stock Titan
Wedbush Cuts Price Target on Denali Therapeutics to $25 From $30, Keeps Outperform Rating - marketscreener.com
Denali Therapeutics (DNLI) CMO details 170,612-share equity stake in Form 3 - Stock Titan
Targeted therapies dominate March’s five NME approvals - BioWorld News
Denali (DNLI) Stock: Why Smart Money Likes It (Investor Interest) 2026-04-20Social Buy Zones - Cổng thông tin điện tử Tỉnh Sơn La
Orsini Selected as the Exclusive Specialty Pharmacy and Home Infusion Partner for Denali Therapeutics' AVLAYAH™ (tividenofusp alfa-eknm) - BioSpace
Technical Reactions to DNLI Trends in Macro Strategies - Stock Traders Daily
DNLI Should I Buy - Intellectia AI
Why Denali Therapeutics (DNLI) Is Up 7.4% After Regaining Full Rights To DNL593 Collaboration - Sahm
DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock? - TradingView
Hunter Syndrome Market to Surpass USD 1.2 Billion by 2036 | 15+ Emerging Therapies and 10+ Companies Driving Innovation, analyses DelveInsight - Barchart
DNLI.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Retail Surge: Can Denali Therapeutics Inc withstand a market correction2026 Drop Watch & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Pullback Watch: Is Denali Therapeutics Inc stock suitable for long term investingQuarterly Trade Report & Smart Money Movement Tracker - baoquankhu1.vn
Denali Therapeutics Inc. $DNLI Shares Acquired by Baillie Gifford & Co. - MarketBeat
Assessing Denali Therapeutics (DNLI) Valuation After Recent Share Pullback And Pipeline Growth Expectations - Sahm
Pullback Watch: Can Denali Therapeutics Inc withstand a market correctionMarket Activity Summary & Community Verified Swing Trade Signals - baoquankhu1.vn
Retail Surge: What are analysts price targets for Denali Therapeutics IncPrice Action & Risk Controlled Swing Alerts - baoquankhu1.vn
Trading the Move, Not the Narrative: (DNLI) Edition - Stock Traders Daily
Q3 EPS Estimate for Denali Therapeutics Increased by Analyst - MarketBeat
How AVLAYAH’s Accelerated Approval and Takeda Exit Will Impact Denali Therapeutics (DNLI) Investors - Sahm
Denali Therapeutics Inc (DNLI) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):